Blog
RSS FeedPosted by Michael Wonder on 14 Sep 2020
Revolutionary cancer medicine Vitrakvi shrinks tumours in days
14 September 2020 - Doctors are amazed by a new cancer medicine offering Australian kids a new lease on life, but ...
Posted by Michael Wonder on 14 Sep 2020
Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions
10 September 2020 - The purpose of this study was to evaluate the current state of health economic evaluations submitted by ...
Posted by Michael Wonder on 13 Sep 2020
Trump says he has signed new executive order to lower drug prices
14 September 2020 - U.S. President Donald Trump said on Sunday he had signed a new executive order aimed at ...
Posted by Michael Wonder on 13 Sep 2020
Agenda for November 2020 PBAC meeting
13 September 2020 - The Department of Health has once revised the agenda for the upcoming November PBAC meeting without ...
Posted by Michael Wonder on 11 Sep 2020
NICE chief executive and chairman thank non-executive director for his service as he announces resignation
11 September 2020 - Professor Martin Cowie stands down from the NICE board following his appointment to a role at Astra ...
Posted by Michael Wonder on 11 Sep 2020
Improved agreement means NICE now recommends lung cancer treatment
11 September 2020 - Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published today by NICE. ...
Posted by Michael Wonder on 11 Sep 2020
Surrogate outcomes in health technology assessment: an international review of methodological guidelines
11 September 2020 - In the drive towards faster patient access to treatments, health technology assessment agencies are increasingly faced with ...
Posted by Michael Wonder on 11 Sep 2020
ICER publishes evidence report on targeted immune modulator therapies for ulcerative colitis
11 September 2020 - All assessed therapies provide significant health benefits, but even after rebates, all are priced at levels ...
Posted by Michael Wonder on 11 Sep 2020
NICE backs Portola's Ondexxya
11 September 2020 - NICE has published the outcome of an appraisal consultation document backing NHS funds for restricted use ...
Posted by Michael Wonder on 11 Sep 2020
Nasal spray medicine for treatment-resistant depression not recommended by NICE
3 September 2020 - Consultation open on draft guidance until Friday 25 September 2020. ...
Posted by Michael Wonder on 11 Sep 2020
Health Canada approves Tremfya (guselkumab injection), a first in class, selective interleukin 23 inhibitor for active psoriatic arthritis
10 September 2020 - Data show Tremfya significantly improved signs and symptoms in joints, skin, and soft tissue of adults with ...
Posted by Michael Wonder on 11 Sep 2020
Medexus reports Health Canada approval of Gleolan for use in guided surgical resection of high grade gliomas
10 September 2020 - Medexus Pharmaceuticals today announces that on 9 September 2020, it received a Notice of Compliance from ...
Posted by Michael Wonder on 11 Sep 2020
NSW boy with severe eczema says he’s ‘tired’ of living with illness as family ask for drug to be subsidised
11 September 2020 - The family of a young NSW boy suffering from a severe skin condition will have to fork ...
Posted by Michael Wonder on 11 Sep 2020
Junshi Biosciences receives FDA breakthrough therapy designation for toripalimab for the treatment of nasopharyngeal carcinoma
10 September 2020 - Junshi Biosciences announced today that the US FDA has recently granted breakthrough therapy designation to toripalimab for ...
Posted by Michael Wonder on 10 Sep 2020
Biosimilar pegfilgrastim on the PBS - information for health professionals and patients
11 September 2020 - A biosimilar brand of pegfilgrastim (Pelgraz) was listed on the PBS on 1 August 2020. ...